DK1531819T3 - Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen - Google Patents

Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Info

Publication number
DK1531819T3
DK1531819T3 DK03753349T DK03753349T DK1531819T3 DK 1531819 T3 DK1531819 T3 DK 1531819T3 DK 03753349 T DK03753349 T DK 03753349T DK 03753349 T DK03753349 T DK 03753349T DK 1531819 T3 DK1531819 T3 DK 1531819T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
pain management
ikappab kinase
ikappab
pain
Prior art date
Application number
DK03753349T
Other languages
Danish (da)
English (en)
Inventor
Martin Michaelis
Olaf Ritzeler
Gerhard Jaehne
Karl Rudolphi
Gerd Geisslinger
Hans-Georg Schaible
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1531819T3 publication Critical patent/DK1531819T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paper (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK03753349T 2002-08-17 2003-08-05 Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen DK1531819T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10237723A DE10237723A1 (de) 2002-08-17 2002-08-17 Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
PCT/EP2003/008628 WO2004022057A1 (fr) 2002-08-17 2003-08-05 UTILISATION D'INHIBITEURS DE L'IλB KINASE DANS LE TRAITEMENT DE LA DOULEUR

Publications (1)

Publication Number Publication Date
DK1531819T3 true DK1531819T3 (da) 2009-04-20

Family

ID=31968975

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03753349T DK1531819T3 (da) 2002-08-17 2003-08-05 Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen

Country Status (34)

Country Link
EP (1) EP1531819B1 (fr)
JP (1) JP4504811B2 (fr)
KR (2) KR101119845B1 (fr)
CN (1) CN100398107C (fr)
AR (1) AR043045A1 (fr)
AT (1) ATE418336T1 (fr)
AU (1) AU2003271555B2 (fr)
BR (1) BR0313555A (fr)
CA (1) CA2495455C (fr)
CO (1) CO5690585A2 (fr)
CR (1) CR7716A (fr)
CY (1) CY1108874T1 (fr)
DE (2) DE10237723A1 (fr)
DK (1) DK1531819T3 (fr)
EC (1) ECSP055609A (fr)
ES (1) ES2320118T3 (fr)
HK (1) HK1079426A1 (fr)
HR (1) HRP20050041B1 (fr)
IL (1) IL166780A (fr)
MA (1) MA27334A1 (fr)
MX (1) MXPA05001218A (fr)
MY (1) MY138059A (fr)
NO (1) NO334309B1 (fr)
OA (1) OA12907A (fr)
PL (1) PL212356B1 (fr)
PT (1) PT1531819E (fr)
RS (1) RS51878B (fr)
RU (1) RU2320338C2 (fr)
SI (1) SI1531819T1 (fr)
TN (1) TNSN05044A1 (fr)
TW (1) TWI325782B (fr)
UA (1) UA80837C2 (fr)
WO (1) WO2004022057A1 (fr)
ZA (1) ZA200500323B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
WO2006019832A1 (fr) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines utilisees pour traiter l'hepatite c
DE102005025225A1 (de) * 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201242962A (en) * 2010-12-01 2012-11-01 Sumitomo Chemical Co Pyrimidine compound and use for pest control thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2532755A1 (fr) * 2011-06-10 2012-12-12 Sanofi-Aventis Procédés et utilisations basés sur l'expression de Slfn2 et liés à l'identification et au profilage de composés pour une utilisation dans le traitement ou la prévention de la douleur
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
PL2787998T3 (pl) * 2011-12-06 2017-04-28 Sanofi Formy krystaliczne [(S)-1-karbamoilo-2-(fenylopirymidyn-2-yloamino) etylo]-amidu kwasu 2-(2-metyloaminopirymidyn-4-ylo)-1H-indolo 5-karboksylowego
EP3184095A1 (fr) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Unitées d'administration comprennante une polymorphe 1 de 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CA2951972A1 (fr) * 2014-07-03 2016-01-07 Sanofi Acide 2-(2-methylamino-pyrimidin-4-yl)-1 h-indole-5-carboxylique [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide utilisable dans le traitement de la douleur associee a l'arthrose
CN112513025A (zh) 2018-07-16 2021-03-16 诺华股份有限公司 用于制备苯基哌啶基吲哚衍生物的化学方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2261248C2 (ru) * 1999-06-23 2005-09-27 Авентис Фарма Дойчланд Гмбх Замещенные бензимидазолы и лекарственное средство на их основе
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
HK1079426A1 (en) 2006-04-07
AU2003271555A1 (en) 2004-03-29
DE10237723A1 (de) 2004-07-08
CN1674899A (zh) 2005-09-28
WO2004022057A1 (fr) 2004-03-18
CA2495455A1 (fr) 2004-03-18
RS20050070A (en) 2007-06-04
PL373568A1 (en) 2005-09-05
HRP20050041A2 (hr) 2006-04-30
ES2320118T3 (es) 2009-05-19
JP4504811B2 (ja) 2010-07-14
OA12907A (en) 2006-10-13
RU2320338C2 (ru) 2008-03-27
RU2005107419A (ru) 2005-08-10
EP1531819B1 (fr) 2008-12-24
KR20050058339A (ko) 2005-06-16
BR0313555A (pt) 2005-07-12
AU2003271555B2 (en) 2009-03-26
PL212356B1 (pl) 2012-09-28
PT1531819E (pt) 2009-02-18
AR043045A1 (es) 2005-07-13
CY1108874T1 (el) 2014-07-02
SI1531819T1 (sl) 2009-06-30
KR20110135428A (ko) 2011-12-16
JP2005539053A (ja) 2005-12-22
CA2495455C (fr) 2011-01-11
EP1531819A1 (fr) 2005-05-25
ECSP055609A (es) 2005-04-18
ATE418336T1 (de) 2009-01-15
RS51878B (sr) 2012-02-29
ZA200500323B (en) 2006-02-22
CN100398107C (zh) 2008-07-02
TW200417370A (en) 2004-09-16
MY138059A (en) 2009-04-30
TWI325782B (en) 2010-06-11
IL166780A (en) 2011-11-30
HRP20050041B1 (hr) 2013-07-31
KR101119845B1 (ko) 2012-02-28
MA27334A1 (fr) 2005-05-02
UA80837C2 (uk) 2007-11-12
NO334309B1 (no) 2014-02-03
IL166780A0 (en) 2006-01-15
DE50310980D1 (de) 2009-02-05
CR7716A (es) 2008-11-25
MXPA05001218A (es) 2005-05-16
TNSN05044A1 (en) 2007-05-14
CO5690585A2 (es) 2006-10-31
NO20051339L (no) 2005-05-03

Similar Documents

Publication Publication Date Title
DK1531819T3 (da) Anvendelse af ikappab kinaseinhibitorer i smertebehandlingen
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
DK1532138T3 (da) Inhibitorer af tyrosinkinaser
IS7599A (is) Heterósýklískir kínasatálmar
HK1078779A1 (en) Substituted benzazoles and use thereof as raf kinase inhibitors
DE60313106D1 (de) Zugangsverwaltung
IS6968A (is) Nýir týrósínkínasa tálmar
ES2867378T8 (es) Epinefrina inhalable
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
NO20021341D0 (no) Autentisering og tilgangsstyring
DE50209166D1 (de) Innenkühlbare Schraube
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
SE0400663L (sv) Hantering av osäkerhet i ledningssystem
NO20044104L (no) Ikke-nukleoside reverstranskriptase-inhibitorer
DE602004022935D1 (de) Verbesserungen des stimulationserfolgs-managements
DE60316425D1 (de) NF-kappaB-INHIBITOREN
DE60229669D1 (de) X-2 inhibitoren
DE60316792D1 (de) Pharmazeutische verwendung von cox-2-hemmern in angiogenese-vermittelten augenerkrankungen
ATE394140T1 (de) Verwendung neuer etonogestrelester
SE0203540D0 (sv) Use of an inhibilor or antagonist against lissue factor
SE0200545D0 (sv) Use of an inhibitor or antagonist against tissue factor
DK1529034T3 (da) Benzoylpyrazoloner substitueret med 3-aminocarbonyl
SE0201844D0 (sv) New methods and use
EE200300187A (et) Peg-seotud proteiinkinaasi inhibiitor ja selle kasutamine